ATE403006T1 - Verwendung eines adenovirusvektors zur transduktion von synovialen zellen - Google Patents

Verwendung eines adenovirusvektors zur transduktion von synovialen zellen

Info

Publication number
ATE403006T1
ATE403006T1 AT00908116T AT00908116T ATE403006T1 AT E403006 T1 ATE403006 T1 AT E403006T1 AT 00908116 T AT00908116 T AT 00908116T AT 00908116 T AT00908116 T AT 00908116T AT E403006 T1 ATE403006 T1 AT E403006T1
Authority
AT
Austria
Prior art keywords
adenovirus
transducing
adenovirus vector
tissue tropism
synovial cells
Prior art date
Application number
AT00908116T
Other languages
German (de)
English (en)
Inventor
Ronald Vogels
Govert Schouten
Abraham Bout
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE403006T1 publication Critical patent/ATE403006T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00908116T 1999-03-04 2000-03-03 Verwendung eines adenovirusvektors zur transduktion von synovialen zellen ATE403006T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99200624 1999-03-04

Publications (1)

Publication Number Publication Date
ATE403006T1 true ATE403006T1 (de) 2008-08-15

Family

ID=8239945

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00908116T ATE403006T1 (de) 1999-03-04 2000-03-03 Verwendung eines adenovirusvektors zur transduktion von synovialen zellen

Country Status (7)

Country Link
EP (1) EP1159438B1 (https=)
JP (1) JP4683727B2 (https=)
AT (1) ATE403006T1 (https=)
AU (1) AU776067B2 (https=)
CA (1) CA2364499C (https=)
DE (1) DE60039683D1 (https=)
WO (1) WO2000052186A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
ATE519855T1 (de) * 1999-05-17 2011-08-15 Crucell Holland Bv Rekombinantes adenovirus des serotyps ad11
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (en) * 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
CA2418977C (en) 2000-08-10 2011-01-18 Crucell Holland B.V. Gene delivery vectors with cell type specificity for primary human chondrocytes
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1195440A1 (en) * 2000-10-06 2002-04-10 Introgene B.V. Gene delivery vectors for stem cells
WO2002029073A2 (en) * 2000-10-06 2002-04-11 Crucell Holland B.V. Gene delivery vectors for stem cells
EP1279738A1 (en) * 2001-07-06 2003-01-29 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
DK1497440T3 (da) 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
KR101021387B1 (ko) 2002-04-25 2011-03-14 크루셀 홀란드 비.브이. 아데노바이러스 벡터를 생산하기 위한 수단 및 방법
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
KR20250081944A (ko) 2014-09-24 2025-06-05 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
EP3359175B1 (en) 2015-10-05 2020-09-16 Salk Institute for Biological Studies Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration
EP4155411A1 (en) 2016-02-23 2023-03-29 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
WO2018125970A1 (en) * 2016-12-30 2018-07-05 Salk Institute For Biological Studies Synthetic adenoviruses targeting bone tissue and uses thereof
CA3064863A1 (en) 2017-05-26 2018-11-29 Epicentrx, Inc. Recombinant adenoviruses carrying transgenes
MX2020010499A (es) 2018-04-09 2020-10-28 Salk Inst For Biological Studi Composiciones de adenovirus oncoliticas con propiedades aumentadas de replicacion.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
SI0833934T2 (sl) * 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
JP3420586B2 (ja) * 1995-11-28 2003-06-23 ジェンベク、インコーポレイティッド 細胞への遣伝子導入のためのベクターおよび方法
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1020529B1 (en) * 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells

Also Published As

Publication number Publication date
AU776067B2 (en) 2004-08-26
AU2948800A (en) 2000-09-21
DE60039683D1 (de) 2008-09-11
JP2002537816A (ja) 2002-11-12
WO2000052186A1 (en) 2000-09-08
CA2364499A1 (en) 2000-09-08
EP1159438B1 (en) 2008-07-30
EP1159438A1 (en) 2001-12-05
CA2364499C (en) 2008-12-23
JP4683727B2 (ja) 2011-05-18

Similar Documents

Publication Publication Date Title
ATE403006T1 (de) Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
Nakamura et al. Early biological effect of in vivo gene transfer of platelet-derived growth factor (PDGF)-B into healing patellar ligament
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
JP2002537816A5 (https=)
EP0701563A4 (en) GEN TRANSFER FOR TREATING CONSTRUCTIVE TISSUE OF A MAMMAL HOST
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
WO2001005434A3 (en) Hyaluronic acid-protein conjugates
HUP0204544A2 (en) Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP2292771A3 (en) Sense mRNA therapy
ATE510847T1 (de) Membrangerüstproteine
US20150231168A1 (en) Methods for sustained and regulatable gene expression using viral based expression vectors
DE69520448D1 (de) Adenovirus-aav zwittervirus sowieverfahrungen zur verwendung davon
DE59913833D1 (de) Strukturprotein von aav, seine herstellung und verwendung
NO995697D0 (no) Gen-vektorer
WO2000061736A3 (en) Recombinant and mutant marek's disease virus
US20220249346A1 (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
EP1026246A4 (en) RECOMBINANTS OF AVIAN INFECTIOUS HERPETIC VIRUS AND RECOMBINANT VACCINES PREPARED THEREWITH
DE69516416D1 (de) Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen
Hu et al. Virus immobilization on biomaterial scaffolds through biotin–avidin interaction for improving bone regeneration
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
AU1281902A (en) Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
AU2347501A (en) Trp-protein-related mtr1 protein and dna sequence coding therefor
WO1999009177A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
FR2756491B1 (fr) Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties